Along the same line, increasing the number of intratumoral CD103+ cDC1 through the administration of Flt3L (Miao et al., 2018), or activating them via TLR3 agonists (Garzon-Muvdi et al., 2018), magnifies the response of mouse glioblastomas to immune checkpoint blockade, suggesting the importance of this DC type to augment immunity against glioblastoma, similar to other tumor types. Here, TLR3 is linked to glioblastoma.